No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug
By Randy Osborne
Friday, October 26, 2012
The ripe market for an acute kidney injury (AKI) therapy good enough to win FDA approval drew Thrasos Therapeutics Inc. into the game, and $35 million in funding should help the company through Phase II trials with THR-184, its lead compound.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.